▶ 調査レポート

世界の呼吸器ウイルス感染症治療薬市場2020年-2030年:薬品種類別(抗生物質、非ステロイド性抗炎症薬[NSAIDS]、咳止め薬、鼻充血除去薬、その他)、感染症別、投与経路別、購入方法別、流通チャンネル別

• 英文タイトル:Respiratory Virus Infection Drugs Market (Drug Type: Antibiotics, Non-Steroidal Anti-Inflammatory Drugs [NSAIDS], Cough Suppressants, Nasal Decongestants, and Others; Infection Type: Respiratory Syncytial Virus [RSV] Infection, Influenza Virus Infection, Parainfluenza Virus Infection, Adenovirus Infection, Rhinovirus Infection, and Others; Route of Administration: Oral and Parenteral; Mode of Purchase: Prescription-based Drugs and Over-the-counter Drugs; and Distribution Channel: Hospital Pharmacies, Drug Stores, Retail Pharmacies, Clinics, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 - 2030

Transparency Market Researchが調査・発行した産業分析レポートです。世界の呼吸器ウイルス感染症治療薬市場2020年-2030年:薬品種類別(抗生物質、非ステロイド性抗炎症薬[NSAIDS]、咳止め薬、鼻充血除去薬、その他)、感染症別、投与経路別、購入方法別、流通チャンネル別 / Respiratory Virus Infection Drugs Market (Drug Type: Antibiotics, Non-Steroidal Anti-Inflammatory Drugs [NSAIDS], Cough Suppressants, Nasal Decongestants, and Others; Infection Type: Respiratory Syncytial Virus [RSV] Infection, Influenza Virus Infection, Parainfluenza Virus Infection, Adenovirus Infection, Rhinovirus Infection, and Others; Route of Administration: Oral and Parenteral; Mode of Purchase: Prescription-based Drugs and Over-the-counter Drugs; and Distribution Channel: Hospital Pharmacies, Drug Stores, Retail Pharmacies, Clinics, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 - 2030 / MRC2102A023資料のイメージです。• レポートコード:MRC2102A023
• 出版社/出版日:Transparency Market Research / 2021年1月4日
• レポート形態:英文、PDF、238ページ
• 納品方法:Eメール
• 産業分類:製薬
• 販売価格(消費税別)
  Single User(1名様閲覧)¥631,655 (USD5,795)▷ お問い合わせ
  Site Licence(同一拠点内共有可)¥958,655 (USD8,795)▷ お問い合わせ
  Enterprisewide Licence(複数拠点内共有可)¥1,285,655 (USD11,795)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
Transparency Market Research社の本市場調査レポートでは、世界の呼吸器ウイルス感染症治療薬市場について調査・分析し、序論、仮定/調査手法、エグゼクティブサマリー、市場概要、キーインサイト、薬品種類別(抗生物質、非ステロイド性抗炎症薬[NSAIDS]、咳止め薬、鼻充血除去薬、その他)分析、感染症別分析、投与経路別分析、購入方法別分析、流通チャンネル別分析、地域別(北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ)分析、競争状況を掲載しています。
・序論
・仮定/調査手法
・エグゼクティブサマリー
・市場概要
・キーインサイト
・世界の呼吸器ウイルス感染症治療薬市場規模:薬品種類別(抗生物質、非ステロイド性抗炎症薬[NSAIDS]、咳止め薬、鼻充血除去薬、その他)
・世界の呼吸器ウイルス感染症治療薬市場規模:感染症別
・世界の呼吸器ウイルス感染症治療薬市場規模:投与経路別
・世界の呼吸器ウイルス感染症治療薬市場規模:購入方法別
・世界の呼吸器ウイルス感染症治療薬市場規模:流通チャンネル別
・世界の呼吸器ウイルス感染症治療薬市場規模:地域別(北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ)
・競争状況

Respiratory Virus Infection Drugs Market – Scope of the Report

TMR’s report on the global respiratory virus infection drugs market studies past as well as current growth trends and opportunities to gain valuable insights of these indicators of the market during the forecast period from 2020 to 2030. The report provides revenue of the global respiratory virus infection drugs market for the period 2018–2030, considering 2019 as the base year and 2030 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global respiratory virus infection drugs market during the forecast period.

The report has been prepared after primary and secondary researches. Primary research involved bulk of research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global respiratory virus infection drugs market.

Secondary research also included Internet sources, statistical data from government agencies, websites, company presentations, sales data, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various phenomenon in the global respiratory virus infection drugs market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Furthermore, the report sheds light on the changing competitive dynamics in the global respiratory virus infection drugs market. These indices serve as valuable tools for existing market players as well as for entities interested in entering the global respiratory virus infection drugs market.

The report delves into the competition landscape of the global respiratory virus infection drugs market. Key players operating in the global respiratory virus infection drugs market have been identified, and each one of these has been profiled for distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players in the global respiratory virus infection drugs market that have been profiled in this report.

Key Questions Answered in Respiratory Virus Infection Drugs Market Report

What is the scope of growth for product companies in the global respiratory virus infection drugs market?
What will be the Y-o-Y growth of the global respiratory virus infection drugs market between 2020 and 2030?
What is the influence of changing trends in technologies on the global respiratory virus infection drugs market?
Will North America continue to be the most profitable market for respiratory virus infection drugs?
Which factors are anticipated to hamper the global respiratory virus infection drugs market during the forecast period?
Which are the leading companies in the global respiratory virus infection drugs market?
Research Methodology

A unique methodology has been utilized by TMR to conduct comprehensive research on the growth of the global respiratory virus infection drugs market and arrive at conclusions on its growth prospects. This research methodology is a combination of primary and secondary research, which helps analysts warrant the accuracy and reliability of the drawn conclusions.

Secondary research sources referred to by analysts during the production of the global respiratory virus infection drugs market report include statistics from company annual reports, SEC filings, company websites, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and market intelligence managers, who contributed to the production of TMR’s study on the respiratory virus infection drugs market as primary methods.

These primary research respondents have provided exclusive information during interviews, which serves as a validation from the respiratory virus infection drugs market leaders. Access to an extensive internal repository and external proprietary databases enabled this report to address specific details and questions about the global respiratory virus infection drugs market with accuracy. The study also uses the top-down approach to assess the revenues of each segment and the bottom-up approach to counter-validate them. This has helped in reaching TMR’s estimates on future prospects of the global respiratory virus infection drugs more reliably and accurately.

レポート目次

1. Preface

1.1. Market Definition and Scope

1.2. Market Segmentation

1.3. Key Research Objectives

1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Respiratory Virus Infection Drugs Market

4. Market Overview

4.1. Introduction

4.1.1. Drug Type Definition

4.1.2. Industry Evolution / Developments

4.2. Overview

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Opportunities

4.4. Global Respiratory Virus Infection Drugs Market Analysis and Forecast, 2018–2030

5. Key Insights

5.1. Healthcare Industry Overview

5.2. Pipeline Analysis (asthma and COPD)

5.3. Regulatory Scenario

5.4. Disease Prevalence Rate in Key Countries

5.5. Key Market Events

5.6. COVID-19 Pandemic Impact on Industry

6. Global Respiratory Virus Infection Drugs Market Analysis and Forecast, by Drug Type

6.1. Introduction & Definition

6.2. Key Findings / Developments

6.3. Market Value Forecast, by Drug Type, 2018–2030

6.3.1. Antibiotics

6.3.2. Non-steroidal Anti-inflammatory Drugs (NSAIDS)

6.3.3. Cough Suppressants

6.3.4. Nasal Decongestants

6.3.5. Others

6.4. Market Attractiveness Analysis, by Drug Type

7. Global Respiratory Virus Infection Drugs Market Analysis and Forecast, by Infection Type

7.1. Introduction & Definition

7.2. Key Findings / Developments

7.3. Market Value Forecast, by Infection Type, 2018–2030

7.3.1. Respiratory Syncytial Virus (RSV) Infection

7.3.2. Influenza Virus Infection

7.3.3. Parainfluenza Virus Infection

7.3.4. Adenovirus Infection

7.3.5. Rhinovirus Infection

7.3.6. Others

7.4. Market Attractiveness Analysis, by Infection Type

8. Global Respiratory Virus Infection Drugs Market Analysis and Forecast, by Route of Administration

8.1. Introduction & Definition

8.2. Key Findings / Developments

8.3. Market Value Forecast, by Route of Administration, 2018–2030

8.3.1. Oral

8.3.2. Parenteral

8.4. Market Attractiveness Analysis, by Route of Administration

9. Global Respiratory Virus Infection Drugs Market Analysis and Forecast, by Mode of Purchase

9.1. Introduction & Definition

9.2. Key Findings / Developments

9.3. Market Value Forecast, by Mode of Purchase, 2018–2030

9.3.1. Prescription-based Drugs

9.3.2. Over-the-Counter Drugs

9.4. Market Attractiveness Analysis, by Mode of Purchase

10. Global Respiratory Virus Infection Drugs Market Analysis and Forecast, by Distribution Channel

10.1. Introduction & Definition

10.2. Key Findings / Developments

10.3. Market Value Forecast, by Distribution Channel, 2018–2030

10.3.1. Hospital Pharmacies

10.3.2. Drug Stores

10.3.3. Retail Pharmacies

10.3.4. Clinics

10.3.5. Others

10.4. Market Attractiveness Analysis, by Distribution Channel

11. Global Respiratory Virus Infection Drugs Market Analysis and Forecast, by Region

11.1. Key Findings

11.2. Market Value Forecast, by Region

11.2.1. North America

11.2.2. Europe

11.2.3. Asia Pacific

11.2.4. Latin America

11.2.5. Middle East & Africa

11.3. Market Attractiveness Analysis, by Country/Region

12. North America Respiratory Virus Infection Drugs Market Analysis and Forecast

12.1. Introduction

12.1.1. Key Findings

12.2. Market Value Forecast, by Drug Type, 2018–2030

12.2.1. Antibiotics

12.2.2. Non-steroidal Anti-inflammatory Drugs (NSAIDS)

12.2.3. Cough Suppressants

12.2.4. Nasal Decongestants

12.2.5. Others

12.3. Market Value Forecast, by Infection Type, 2018–2030

12.3.1. Respiratory syncytial viruses (RSV) Infection

12.3.2. Influenza Virus Infection

12.3.3. Parainfluenza Virus Infection

12.3.4. Adenovirus Infection

12.3.5. Rhinovirus Infection

12.3.6. Others

12.4. Market Value Forecast, by Route of Administration, 2018–2030

12.4.1. Oral

12.4.2. Parenteral

12.5. Market Value Forecast, by Mode of Purchase, 2018–2030

12.5.1. Prescription-based Drugs

12.5.2. Over-the-Counter Drugs

12.6. Market Value Forecast, by Distribution Channel, 2018–2030

12.6.1. Hospital Pharmacies

12.6.2. Drug Stores

12.6.3. Retail Pharmacies

12.6.4. Clinics

12.6.5. Others

12.7. Market Value Forecast, by Country, 2018–2030

12.7.1. U.S.

12.7.2. Canada

12.8. Market Attractiveness Analysis

12.8.1. By Drug Type

12.8.2. By Infection Type

12.8.3. By Route Of Administration

12.8.4. By Mode of Purchase

12.8.5. By Distribution Channel

12.8.6. By Country

13. Europe Respiratory Virus Infection Drugs Market Analysis and Forecast

13.1. Introduction

13.1.1. Key Findings

13.2. Market Value Forecast, by Drug Type, 2018–2030

13.2.1. Antibiotics

13.2.2. Non-steroidal Anti-inflammatory Drugs (NSAIDS)

13.2.3. Cough Suppressants

13.2.4. Nasal Decongestants

13.2.5. Others

13.3. Market Value Forecast, by Infection Type, 2018–2030

13.3.1. Respiratory Syncytial Virus (RSV) Infection

13.3.2. Influenza Virus Infection

13.3.3. Parainfluenza Virus Infection

13.3.4. Adenovirus Infection

13.3.5. Rhinovirus Infection

13.3.6. Others

13.4. Market Value Forecast, by Route of Administration, 2018–2030

13.4.1. Oral

13.4.2. Parenteral

13.5. Market Value Forecast, by Mode of Purchase, 2018–2030

13.5.1. Prescription-based Drugs

13.5.2. Over-the-Counter Drugs

13.6. Market Value Forecast, by Distribution Channel, 2018–2030

13.6.1. Hospital Pharmacies

13.6.2. Drug Stores

13.6.3. Retail Pharmacies

13.6.4. Clinics

13.6.5. Others

13.7. Market Value Forecast, by Country/Sub-region, 2018–2030

13.7.1. Germany

13.7.2. U.K.

13.7.3. France

13.7.4. Spain

13.7.5. Italy

13.7.6. Rest of Europe

13.8. Market Attractiveness Analysis

13.8.1. By Drug Type

13.8.2. By Infection Type

13.8.3. By Route Of Administration

13.8.4. By Mode of Purchase

13.8.5. By Distribution Channel

13.8.6. By Country/Sub-region

14. Asia Pacific Respiratory Virus Infection Drugs Market Analysis and Forecast

14.1. Introduction

14.1.1. Key Findings

14.2. Market Value Forecast, by Drug Type, 2018–2030

14.2.1. Antibiotics

14.2.2. Non-steroidal Anti-inflammatory Drugs (NSAIDS)

14.2.3. Cough Suppressants

14.2.4. Nasal Decongestants

14.2.5. Others

14.3. Market Value Forecast, by Infection Type, 2018–2030

14.3.1. Respiratory Syncytial Virus (RSV) Infection

14.3.2. Influenza Virus Infection

14.3.3. Parainfluenza Virus Infection

14.3.4. Adenovirus Infection

14.3.5. Rhinovirus Infection

14.3.6. Others

14.4. Market Value Forecast, by Route Of Administration, 2018–2030

14.4.1. Oral

14.4.2. Parenteral

14.5. Market Value Forecast, by Mode of Purchase, 2018–2030

14.5.1. Prescription-based Drugs

14.5.2. Over-the-Counter Drugs

14.6. Market Value Forecast, by Distribution Channel, 2018–2030

14.6.1. Hospital Pharmacies

14.6.2. Drug Stores

14.6.3. Retail Pharmacies

14.6.4. Clinics

14.6.5. Others

14.7. Market Value Forecast, by Country/Sub-region, 2018–2030

14.7.1. China

14.7.2. Japan

14.7.3. India

14.7.4. Australia & New Zealand

14.7.5. Rest of Asia Pacific

14.8. Market Attractiveness Analysis

14.8.1. By Drug Type

14.8.2. By Infection Type

14.8.3. By Route of Administration

14.8.4. By Mode of Purchase

14.8.5. By Distribution Channel

14.8.6. By Country/Sub-region

15. Latin America Respiratory Virus Infection Drugs Market Analysis and Forecast

15.1. Introduction

15.1.1. Key Findings

15.2. Market Value Forecast, by Drug Type, 2018–2030

15.2.1. Antibiotics

15.2.2. Non-steroidal Anti-inflammatory Drugs (NSAIDS)

15.2.3. Cough Suppressants

15.2.4. Nasal Decongestants

15.2.5. Others

15.3. Market Value Forecast, by Infection Type, 2018–2030

15.3.1. Respiratory Syncytial Virus (RSV) Infection

15.3.2. Influenza Virus Infection

15.3.3. Parainfluenza Virus Infection

15.3.4. Adenovirus Infection

15.3.5. Rhinovirus Infection

15.3.6. Others

15.4. Market Value Forecast, by Route of Administration, 2018–2030

15.4.1. Oral

15.4.2. Parenteral

15.5. Market Value Forecast, by Mode of Purchase, 2018–2030

15.5.1. Prescription-based Drugs

15.5.2. Over-the-Counter Drugs

15.6. Market Value Forecast, by Distribution Channel, 2018–2030

15.6.1. Hospital Pharmacies

15.6.2. Drug Stores

15.6.3. Retail Pharmacies

15.6.4. Clinics

15.6.5. Others

15.7. Market Value Forecast, by Country/Sub-region, 2018–2030

15.7.1. Brazil

15.7.2. Mexico

15.7.3. Rest of Latin America

15.8. Market Attractiveness Analysis

15.8.1. By Drug Type

15.8.2. By Infection Type

15.8.3. By Route of Administration

15.8.4. By Mode of Purchase

15.8.5. By Distribution Channel

15.8.6. By Country/Sub-region

16. Middle East & Africa Respiratory Virus Infection Drugs Market Analysis and Forecast

16.1. Introduction

16.1.1. Key Findings

16.2. Market Value Forecast, by Drug Type, 2018–2030

16.2.1. Antibiotics

16.2.2. Non-steroidal Anti-inflammatory Drugs (NSAIDS)

16.2.3. Cough Suppressants

16.2.4. Nasal Decongestants

16.2.5. Others

16.3. Market Value Forecast, by Infection Type, 2018–2030

16.3.1. Respiratory Syncytial Virus (RSV) Infection

16.3.2. Influenza Virus Infection

16.3.3. Parainfluenza Virus Infection

16.3.4. Adenovirus Infection

16.3.5. Rhinovirus Infection

16.3.6. Others

16.4. Market Value Forecast, by Route of Administration, 2018–2030

16.4.1. Oral

16.4.2. Parenteral

16.5. Market Value Forecast, by Mode of Purchase, 2018–2030

16.5.1. Prescription-based Drugs

16.5.2. Over-the-Counter Drugs

16.6. Market Value Forecast, by Distribution Channel, 2018–2030

16.6.1. Hospital Pharmacies

16.6.2. Drug Stores

16.6.3. Retail Pharmacies

16.6.4. Clinics

16.6.5. Others

16.7. Market Value Forecast, by Country/Sub-region, 2018–2030

16.7.1. GCC Countries

16.7.2. South Africa

16.7.3. Rest of Middle East & Africa

16.8. Market Attractiveness Analysis

16.8.1. By Drug Type

16.8.2. By Infection Type

16.8.3. By Route of Administration

16.8.4. By Mode of Purchase

16.8.5. By Distribution Channel

16.8.6. By Country/Sub-region

17. Competition Landscape

17.1. Market Player – Competition Matrix (by tier and size of companies)

17.2. Market Share Analysis/Ranking, by Company, 2019

17.3. Company Profiles

17.3.1. GlaxoSmithKline plc

17.3.1.1. Company Overview

17.3.1.2. Company Financials

17.3.1.3. Growth Strategies

17.3.1.4. SWOT Analysis

17.3.2. Merck & Co., Inc.

17.3.2.1. Company Overview

17.3.2.2. Company Financials

17.3.2.3. Growth Strategies

17.3.2.4. SWOT Analysis

17.3.3. AstraZeneca

17.3.3.1. Company Overview

17.3.3.2. Company Financials

17.3.3.3. Growth Strategies

17.3.3.4. SWOT Analysis

17.3.4. Boehringer Ingelheim International GmbH

17.3.4.1. Company Overview

17.3.4.2. Company Financials

17.3.4.3. Growth Strategies

17.3.4.4. SWOT Analysis

17.3.5. F. Hoffmann-La Roche Ltd.

17.3.5.1. Company Overview

17.3.5.2. Company Financials

17.3.5.3. Growth Strategies

17.3.5.4. SWOT Analysis

17.3.6. Teva Pharmaceutical Industries Ltd.

17.3.6.1. Company Overview

17.3.6.2. Company Financials

17.3.6.3. Growth Strategies

17.3.6.4. SWOT Analysis

17.3.7. Sanofi

17.3.7.1. Company Overview

17.3.7.2. Company Financials

17.3.7.3. Growth Strategies

17.3.7.4. SWOT Analysis

17.3.8. Cipla, Inc.

17.3.8.1. Company Overview

17.3.8.2. Company Financials

17.3.8.3. Growth Strategies

17.3.8.4. SWOT Analysis

17.3.9. CHIESI Farmaceutici S.p.A.

17.3.9.1. Company Overview

17.3.9.2. Company Financials

17.3.9.3. Growth Strategies

17.3.9.4. SWOT Analysis

17.3.10. Orion Corporation

17.3.10.1. Company Overview

17.3.10.2. Growth Strategies

17.3.10.3. SWOT Analysis

List of Tables

Table 01: Global Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2018–2030

Table 02: Global Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Infection Type, 2018–2030

Table 03: Global Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 04: Global Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2018–2030

Table 05: Global Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 06: Global Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Region, 2018–2030

Table 07: North America Respiratory Virus Infection Drugs Market Revenue (US$ Mn) Forecast, by Country, 2018–2030

Table 08: North America Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2018–2030

Table 09: North America Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Infection Type, 2018–2030

Table 10: North America Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 11: North America Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Mode of Purchase, 2018–2030

Table 12: North America Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 13: Europe Respiratory Virus Infection Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 14: Europe Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2018–2030

Table 15: Europe Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Infection Type, 2018–2030

Table 16: Europe Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 17: Europe Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Mode of Purchase, 2018–2030

Table 18: Europe Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 19: Asia Pacific Respiratory Virus Infection Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 20: Asia Pacific Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2018–2030

Table 21: Asia Pacific Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Infection Type, 2018–2030

Table 22: Asia Pacific Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 23: Asia Pacific Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Mode of Purchase, 2018–2030

Table 24: Asia Pacific Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 25: Latin America Respiratory Virus Infection Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 26: Latin America Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2018–2030

Table 27: Latin America Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Infection Type, 2018–2030

Table 28: Latin America Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 29: Latin America Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Mode of Purchase, 2018–2030

Table 30: Latin America Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 31: Middle East & Africa Respiratory Virus Infection Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 32: Middle East & Africa Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2018–2030

Table 33: Middle East & Africa Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Infection Type, 2018–2030

Table 34: Middle East & Africa Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 35: Middle East & Africa Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Mode of Purchase, 2018–2030

Table 36: Middle East & Africa Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030